Project Summary Acute kidney injury (AKI) is an increasingly prevalent worldwide problem that has a significant impact on patient mortality and morbidity, including a marked increased risk of progressive chronic kidney disease (CKD). Despite this, no therapies have been shown to accelerate recovery or prevent progression to CKD in patients with AKI. There are several reasons for this, but a major factor has been the lack of effective collaborative pipelines between bench researchers studying the mechanisms and therapeutic approaches for AKI, and clinical scientists implementing hypothesis testing clinical trials in patients with AKI. However, aside from the annual scientific meeting of the American Society of Nephrology (ASN), there are no other established forums that promote direct exchange of ideas between the clinical and basic science AKI research communities. To address this, we are seeking support for the 2nd FASEB “AKI from bench to bedside” conference, which will be held May 14th- 17th 2022, at the Banff Center for the Arts and Creativity in Canada. The aims of this conference series are: 1) to review state of the art and work in progress, basic, translational, and clinical research on AKI; 2) to provide a platform to help develop new investigators trained to think in a more translational way about AKI; 3) to provide a forum for networking across disciplines, including patient advocacy and URM scientists; and 4) to provide a workforce development program for trainees with opportunities to meet and develop long-term mentoring relationships with leaders in their field; career advice; and discussions about challenging topics for research leadership including imposter syndrome and unconscious bias in research. This planned biannual meeting was first held in 2019 in Asilomar, but the 2nd conference was delayed in 2021 in preference for an in-person meeting in 2022, with greater opportunities for networking across disciplines. 30 experts and trainees (34% trainees; 50% female or transgender; and 23% URM) who have confirmed attendance will provide state of the art and work in progress talks on topical aspects of research in the basic and clinical science of AKI. These presentations will be intermingled with additional abstract selected presentations largely from trainees, as well as an informal poster session to encourage scientific interactions between diverse AKI scientists. With an enhanced drive for sponsorship support, we will also defray the costs of registration to attract more trainees and junior faculty to the meeting. On this basis, we expect the meeting will attract clinical and basic scientists from academia, and investigators and leaders from companies involved in pre-clinical and clinical AKI research from across the globe.